1. Inicio
  2. Publicaciones
  3. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease

Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease

Fecha de publicación: Fecha Ahead of Print:

Autores de IDIVAL

Autores ajenos al IDIVAL

  • Marti-Aguado, David
  • Calleja, Jose Luis
  • Vilar-Gomez, Eduardo
  • Rodriguez-Duque, Juan Carlos
  • Puchades, Laura
  • Rivera-Esteban, Jesus
  • Perello, Christie
  • Gomez-Medina, Concepcion
  • Escudero-Garcia, Desamparados
  • Serra, Miguel A
  • Bataller, Ramon

Unidades

Abstract

Background & Aims: Both metabolic dysfunction and alcohol consumption cause steatotic liver disease (SLD). The distinction between metabolic dysfunction-associated SLD (MASLD) and MetALD categories is based on arbitrary thresholds of alcohol intake. Thus, we assessed the impact of different levels of alcohol consumption on SLD severity and their interaction with metabolic comorbidities. Methods: We performed a population-based study with transient elastography (FibroScan((R))) data from participants in Spain (derivation cohort) and the US (validation cohort). A controlled attenuation parameter >= 275 dB/m was used to define SLD. At least one cardiometabolic risk factor was required to define MASLD. Among patients with MASLD, low alcohol consumption was defined as an average of 5-9 drinks/week, moderate consumption as 10-13 drinks/week for females and 10-20 drinks/week for males, and increased alcohol intake (MetALD) as 14-35 drinks/week for females and 21-42 drinks/week for males. Significant fibrosis was defined as a liver stiffness measurement >= 8 kPa and at-risk metabolic dysfunction-associated steatohepatitis (MASH) as a FAST score >= 0.35. Results: The derivation cohort included 2,227 individuals with MASLD (9% reported low, 14% moderate alcohol consumption) and 76 cases with MetALD. Overall prevalences of significant fibrosis and at-risk MASH were 7.6% and 14.8%, respectively. In the multivariable analysis, alcohol consumption was independently associated with significant fibrosis and at-risk MASH. A dose-dependent increase in the prevalence of significant fibrosis and at-risk MASH was observed between the number of drinks/week and the number of cardiometabolic factors. The validation cohort included 1,732 participants with MASLD, of whom 17% had significant fibrosis and 13% at-risk MASH. This cohort validated the association between moderate intake and MASLD at risk of progression (odds ratio 1.69, 95% CI 1.06-2.71). Conclusions: Moderate alcohol intake is commonly seen in MASLD and increases the risk of advanced disease to a level similar to that observed in MetALD. (c) 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Datos de la publicación

ISSN/ISSNe:
1600-0641, 1600-0641

JOURNAL OF HEPATOLOGY  ELSEVIER SCIENCE BV

Tipo:
Article
Páginas:
930-940
PubMed:
38971533

Citas Recibidas en Web of Science: 69

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Campos de Estudio

Financiación

INSTITUTO DE SALUD CARLOS III. (PI15/02138)
INSTITUTO DE SALUD CARLOS III. (PIE15/00079)
Merck Sharp and Dohme (52863)

Proyectos asociados

Disfunción endotelial, ateromatosis subclínica y miocardiopatía en pacientes con infección por VHC. Caracterización y potencial reversibilidad con agentes antivirales directos.

Investigador Principal: Javier Crespo García

PI15/02138 . INSTITUTO DE SALUD CARLOS III. . 2016

Personalized Medicine in HCV infection: understanding and predicting hepatic and systemic responses in the era of the new antiviral drugs.

Investigador Principal: Javier Crespo García

PIE15/00079 . INSTITUTO DE SALUD CARLOS III. . 2016

Compartir